Olodaterol for the treatment of chronic obstructive pulmonary disease
Purpose. Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting β2-agonist (LABA) olodaterol are reviewed. Summary. Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for β2-adrenergic receptors, is indicated for the...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| التنسيق: | article |
| منشور في: |
2016
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/4488 http://dx.doi.org/10.2146/ajhp150364 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/73/15/1135/5101552 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513463667130368 |
|---|---|
| author | Ramadan, Wijdan H. |
| author2 | Kabbara, Wissam K. Abilmona, Rosa M. |
| author2_role | author author |
| author_facet | Ramadan, Wijdan H. Kabbara, Wissam K. Abilmona, Rosa M. |
| author_role | author |
| dc.creator.none.fl_str_mv | Ramadan, Wijdan H. Kabbara, Wissam K. Abilmona, Rosa M. |
| dc.date.none.fl_str_mv | 2016-10-03T09:32:32Z 2016-10-03T09:32:32Z 2016 2016-10-03 |
| dc.identifier.none.fl_str_mv | 1695-0674 http://hdl.handle.net/10725/4488 http://dx.doi.org/10.2146/ajhp150364 Ramadan, W. H., Kabbara, W. K., & Abilmona, R. M. (2016). Olodaterol for the treatment of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy, 73(15). http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/73/15/1135/5101552 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | American Journal of Health-System Pharmacy |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Olodaterol for the treatment of chronic obstructive pulmonary disease |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Purpose. Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting β2-agonist (LABA) olodaterol are reviewed. Summary. Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for β2-adrenergic receptors, is indicated for the treatment of chronic obstructive pulmonary disease (COPD); the recommended dose is 5 µg, to be delivered once daily via the Respimat inhaler. In 48- and 6-week Phase III clinical trials of olodaterol evaluating various lung function and symptomatic outcomes in patients with moderate to very severe COPD, olodaterol use was associated with significant improvements in spirometry outcomes, such as postbronchodilator forced expiratory volume in one second (FEV1), as well as dyspnea severity and quality-of-life measures. Other clinical trials demonstrated that olodaterol produced beneficial effects on FEV1 measures throughout the 24-hour dosing interval. A meta-analysis of data from 20 published research reports indicated that olodaterol's efficacy was comparable to that of the once-daily LABA in-dacaterol and that the combination of olodaterol and tiotropium provided improvements in lung function greater than those provided by tiotropium alone. Analysis of pooled data from four long-term trials showed that olodaterol's safety profile was comparable to that of formoterol; the most frequently reported adverse effects associated with olodaterol use were bronchitis, nasopharyngitis, and upper respiratory tract infection. Conclusion. Once-daily olodaterol 5 µg is an effective therapy in improving lung function and symptomatic outcomes in patients with moderate to very severe COPD receiving other maintenance therapy, with a satisfactory safety profile |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_8bd22cd3de85f0c140984c02285b0d87 |
| identifier_str_mv | 1695-0674 Ramadan, W. H., Kabbara, W. K., & Abilmona, R. M. (2016). Olodaterol for the treatment of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy, 73(15). |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/4488 |
| publishDate | 2016 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Olodaterol for the treatment of chronic obstructive pulmonary diseaseRamadan, Wijdan H.Kabbara, Wissam K.Abilmona, Rosa M.Purpose. Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting β2-agonist (LABA) olodaterol are reviewed. Summary. Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for β2-adrenergic receptors, is indicated for the treatment of chronic obstructive pulmonary disease (COPD); the recommended dose is 5 µg, to be delivered once daily via the Respimat inhaler. In 48- and 6-week Phase III clinical trials of olodaterol evaluating various lung function and symptomatic outcomes in patients with moderate to very severe COPD, olodaterol use was associated with significant improvements in spirometry outcomes, such as postbronchodilator forced expiratory volume in one second (FEV1), as well as dyspnea severity and quality-of-life measures. Other clinical trials demonstrated that olodaterol produced beneficial effects on FEV1 measures throughout the 24-hour dosing interval. A meta-analysis of data from 20 published research reports indicated that olodaterol's efficacy was comparable to that of the once-daily LABA in-dacaterol and that the combination of olodaterol and tiotropium provided improvements in lung function greater than those provided by tiotropium alone. Analysis of pooled data from four long-term trials showed that olodaterol's safety profile was comparable to that of formoterol; the most frequently reported adverse effects associated with olodaterol use were bronchitis, nasopharyngitis, and upper respiratory tract infection. Conclusion. Once-daily olodaterol 5 µg is an effective therapy in improving lung function and symptomatic outcomes in patients with moderate to very severe COPD receiving other maintenance therapy, with a satisfactory safety profilePublishedN/A2016-10-03T09:32:32Z2016-10-03T09:32:32Z20162016-10-03Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1695-0674http://hdl.handle.net/10725/4488http://dx.doi.org/10.2146/ajhp150364Ramadan, W. H., Kabbara, W. K., & Abilmona, R. M. (2016). Olodaterol for the treatment of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy, 73(15).http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://academic.oup.com/ajhp/article-abstract/73/15/1135/5101552enAmerican Journal of Health-System Pharmacyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/44882021-03-19T10:00:55Z |
| spellingShingle | Olodaterol for the treatment of chronic obstructive pulmonary disease Ramadan, Wijdan H. |
| status_str | publishedVersion |
| title | Olodaterol for the treatment of chronic obstructive pulmonary disease |
| title_full | Olodaterol for the treatment of chronic obstructive pulmonary disease |
| title_fullStr | Olodaterol for the treatment of chronic obstructive pulmonary disease |
| title_full_unstemmed | Olodaterol for the treatment of chronic obstructive pulmonary disease |
| title_short | Olodaterol for the treatment of chronic obstructive pulmonary disease |
| title_sort | Olodaterol for the treatment of chronic obstructive pulmonary disease |
| url | http://hdl.handle.net/10725/4488 http://dx.doi.org/10.2146/ajhp150364 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/73/15/1135/5101552 |